Author: openjargon

Fortunately for investors, there are a lot of options to choose from in the Australian gold sector.

One ASX 200 gold stock that could be worth considering according to Bell Potter is Genesis Minerals Ltd (ASX: GMD).

In fact, the broker thinks this miner could be cheap at current levels. Let’s see what it is saying about this stock.

What is the broker saying?

Bell Potter notes that it is expecting the ASX 200 gold stock to deliver production a touch ahead of consensus expectations in the third quarter.

And while this still means lower production quarter on quarter, this is due to downtime relating to a change of contractor at the Gwalia operation.

In addition, the broker is expecting only a minor impact to costs from higher diesel prices for this quarter. However, it sees potential for costs to rise in future quarters if availability issues remain. It explains:

We forecast 3Q production of ~70koz (VA 69.5koz) which implies a slight reduction on QoQ production (74koz). We had assumed some downtime/ interruptions in productivity at Gwalia due to the change over in contractors, resulting in a forecast that was more conservative. Elsewhere, we see a continuation in performance from 2Q, with total processed grade declining slightly (2.3g/t to 2.1g/t). Our internal modelling suggests a minor impact to AISC from rising diesel costs with diesel representing ~4% (A$108/oz) of AISC prior to the closure of the Strait of Hormuz.

Assuming a ~75% increase in diesel costs sees the impact jump to ~A$199/oz. Should availability issues persist, GMD will be impacted alongside the rest of the WA mining industry, however there may be some internal levers which GMD may be able to pull to minimize the impact, focusing on Gwalia and stockpiled material through the mill would be the starting point.

An ASX 200 gold stock offering compelling value

In light of the above, Bell Potter believes that Genesis Minerals shares offer “compelling value” at current prices.

This is especially the case give its positive view on the gold price outlook. It explains:

We remain positive on the outlook for gold, given the ongoing tensions in the Middle East which has seen the commodity recover from recent lows of ~US$4,130/oz up to spot of ~US$4,746/oz (+15% from the low, -7.9% MoM). The GDX appears to have outperformed the underlying commodity, with MoM decline of only -3.16% and a rally from the low in Mar-26 of ~23%. On a 12m forward EV/EBITDA basis GMD has contracted to ~6.2x NTM EBITDA vs its peak of ~8x in Sep-25.

This places GMD slightly above Northern Star (NST, Buy TP$35) (5.1x NTM) but below Evolution (EVN, Buy TP$16.60) (7.1x NTM) in our mid-large cap gold coverage. The upcoming (1QFY27) long-term guidance targeting 500kozpa is likely to focus on two aspects we believe: (1) development of Tower Hill and a standalone 3.5-4Mtpa mill which should offset higher cost processing at Leonora and (2) development for Lady Julie (MAU transaction) which would supplement the Laverton mill with higher grade tonnes.

According to the note, Bell Potter has put a buy rating and $9.90 price target on the ASX 200 gold stock.

Based on its current share price of $6.47, this implies potential upside of 53% for investors over the next 12 months.

The post Which cheap ASX 200 gold stock could rise over 50%? appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 ASX shares I’d buy with $10,000 this week
• Here are the top 10 ASX 200 shares today
• ASX gold shares tumble as bull run faces its first big test in 1Q CY26
• Why ASX 200 gold stocks like Northern Star and Evolution Mining are storming higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Fortescue Ltd (ASX: FMG) shares are under slight pressure on Friday after the miner detailed the next stage of its Pilbara renewable rollout.

In morning trade, the Fortescue share price is down a modest 1.56% to $20.21.

Despite the dip, its 12-month gain sits at 35%, with the stock still well above where it traded this time last year.

Even with the shares easing today, the latest ASX announcement outlines plans to accelerate what it says is the world’s first replicable large-scale heavy industry green grid.

Let’s take a closer look at the release.

Fortescue brings forward giant Pilbara green grid rollout

The latest update is centred on Fortescue’s Pilbara operations, where it is moving faster on the rollout of an integrated renewable energy network. The goal is to replace diesel across some of its biggest mining assets.

Management said the system is expected to reach 290MW of installed renewable capacity by the end of this year, enough to power daytime “green processing” at its Pilbara iron ore facilities.

Later this year, the company expects the grid to run parts of its operations for 24-hour periods without fossil fuels, a milestone that moves its ‘Real Zero’ strategy ahead of the previously targeted December 2030 timeline.

By the end of 2028, Fortescue said the Pilbara network is expected to scale to 1.2GW of solar, more than 600MW of wind generation, and 4 to 5GWh of battery storage.

The company also said the wider profitable decarbonisation program is now targeting around 2GW of generation capacity, with future expansion phases potentially delivered over an 18-month period.

This includes electrification across fixed plant operations, AI-driven iron ore processing infrastructure, rail and port logistics, and on-site accommodation supporting around 10,000 workers.

Why investors may be looking beyond iron ore

Investors seem to be looking at what this project could mean beyond lower emissions.

Fortescue expects the first deployment phase to remove around US$100 million in fossil fuel costs next year. It is also anticipating site unit costs falling by at least US$2 to US$4 per metric tonne.

Management said the technology stack, battery systems, AI optimisation tools, and rollout model are all being designed to be replicable and licensable globally.

That gives investors a better sense of how this could become a second business alongside iron ore, which remains its biggest money maker.

Foolish bottom line

I think this is another positive step for Fortescue. The company is still using its iron ore business to fund growth, while also building out a second area through large-scale energy projects.

To me, that looks like the right direction for the long term. It adds diversification beyond iron ore. I think holding a sensible portion of shares in Fortescue could be a solid investment for investors comfortable with the ups and downs of commodity prices.

The post Fortescue shares ease, but this major update could keep momentum building appeared first on The Motley Fool Australia.

More reading

• Fortescue accelerates world’s first large-scale industrial green energy grid
• Fortescue shares: 3 reasons to buy and 3 reasons to sell
• Buying ASX 200 mining shares? Here’s how Rio Tinto, Fortescue and BHP stacked up in March
• ASX 200 mining shares ride a rollercoaster in March quarter
• 3 reasons why this could be a great time to buy Fortescue shares!

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are charging higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $13.64. In early morning trade on Friday, shares are changing hands for $14.14 apiece, up 3.7%.

For some context, the ASX 200 is down 0.6% at this same time.

With today’s intraday lift factored in, Telix shares are now up an impressive 31.4% since market close on 11 March.

Here’s what’s piquing ASX investor interest today.

Telix shares jump on FDA acceptance

Telix shares are marching higher after the company announced that the United States Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px1.

TLX101-Px1, or Pixclara, is the company’s glioma (brain cancer) imaging agent.

The FDA is aiming for a Prescription Drug User Fee Act (PDUFA) date on 11 September.

That date is achievable, as Pixclara holds both Orphan Drug and Fast Track designations in the US.

The company said that the FDA approval of Pixclara will help meet the significant unaddressed medical need for the characterisation of recurrent or progressive glioma from treatment-related changes in both adult and paediatric patients.

Telix noted that neuroimaging of glioma with 18F-FET (a radioactive imaging tracer) is already broadly recommended in international clinical practice guidelines.

FDA approval would open up the huge US medical market for Pixclara. However, Telix said it is not yet including any potential revenue from future sales in its full-year FY 2026 financial guidance.

What did management say?

“The FDA’s acceptance of our NDA resubmission is an important milestone for Telix,” Kevin Richardson, CEO Telix Precision Medicine, said. “We appreciate the FDA’s constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients.”

Commenting on the FDA acceptance helping to boost Telix shares today, Thomas Hope – Vice Chair, Department of Radiology and Biomedical Imaging at the University of California, San Francisco – said:

There remains a critical unmet need in improving our ability to image residual glioma after treatment. We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET9 available to patients in the United States.

Patrick Wen, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added:

Distinguishing tumour progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with 18F-FET is an important tool in clinical practice worldwide, and the FDA’s acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States.

With today’s intraday gains factored in, Telix shares remain down 46.8% over 12 months.

The post Up 31% in a month, why are Telix shares lifting off again on Friday? appeared first on The Motley Fool Australia.

More reading

• Where is the value amongst ASX healthcare shares?
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• Top brokers name 3 ASX shares to buy today
• 5 things to watch on the ASX 200 on Wednesday
• Why rebounding Telix shares could still rise 40%

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Magellan Financial Group Ltd (ASX: MFG) share price is in focus following news of a proposed full merger with Barrenjoey Capital Partners Group Holdings. The company highlighted its increased stake and support from shareholders for the transaction.

What did Magellan Financial Group report?

• Magellan will acquire the remaining shares in Barrenjoey Capital Partners, increasing its ownership to 100%
• The merger values Barrenjoey at $1.616 billion on a 100% basis
• Barrenjoey delivered $108 million in NPATA (Net Profit After Tax and Amortisation) over the last twelve months to December 2025
• Last twelve months’ revenue for the combined group amounted to $313 million, with Magellan managing $37.5 billion in assets as at 31 March 2026
• Shareholders strongly supported the share issuance, with 91.2% voting in favour

What else do investors need to know?

The merger will unify the businesses, broadening Magellan’s service offering in advisory, capital markets, equities, research, and private capital. Magellan lifted its economic interest in Barrenjoey to 46.4% after purchasing an extra ~10% from Barclays in March 2026, funded via an institutional placement and oversubscribed Share Purchase Plan (SPP).

The Share Purchase Plan saw significant demand, with scale-backs applied to ensure a fair allocation for all eligible investors. The combined group is aiming for a stronger, diversified platform with global reach and a sharpened focus on client outcomes.

What’s next for Magellan Financial Group?

Completion of the merger is subject to several conditions, including regulatory and shareholder approvals, but is progressing with strong support. Management expects the merged group will have enhanced career opportunities, increased scale, and improved balance sheet resilience to navigate market cycles.

Looking ahead, Magellan plans to accelerate growth across public and private markets while leveraging both companies’ expertise and client relationships. The board sees the merger as a compelling case for long-term value creation.

Magellan Financial Group share price snapshot

Over the past 12 months, Magellan Financial Group shares have risen 28%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Magellan Financial Group shares in focus following Barrenjoey merger approval appeared first on The Motley Fool Australia.

More reading

• Monadelphous wins $145m of new and renewed resources sector contracts
• Fortescue accelerates world’s first large-scale industrial green energy grid
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Northern Star Resources Ltd (ASX: NST) shares are a popular option for investors looking for exposure to the gold sector.

But are they a good option after falling heavily from their highs? Let’s see what Bell Potter is saying.

What is the broker saying?

Bell Potter highlights that Northern Star will be releasing its eagerly anticipated quarterly update this month.

While the miner’s production numbers for the third quarter are now known, its costs will be the main focal point. The broker sees risks that management will be forced to downgrade its cost guidance for FY 2026. It said:

NST announced last week it had produced 381koz over the 3Q (+10% QoQ, VA 366koz BPe 353koz), despite the headwinds highlighted in the Mar-13 downgrade. NST are now 74% through the revised production guidance of 1,500koz, which requires a result of at least 391koz (+2.3% QoQ) to meet the twice revised guidance. On our numbers, that will still require a material lift across the portfolio, particularly in throughput and grade at KCGM. The pre-reported result was a beat on our estimates and consensus for 3Q, and, whilst we still anticipate production at the low end of guidance there may be signs that NST has hit the bottom of the downgrade cycle.

Fuel costs will present a headwind heading into the 4Q, accounting for ~5% of AISC prior to the Middle East conflict. We continue to see risks that the AISC guidance of A$2,600/oz – $2,800/oz is at risk given the recent production guidance downgrade (~100koz) and the increase in fuel costs expected to impact the 4Q result. We suspect NST, much like peers in the space, will pull as many levers as possible to prioritise high-value tonnes and delaying any non-essential waste movement, to manage the near-term impacts.

Outside this, the broker highlights that Northern Star’s $500 million share buyback could be interpreted as a sign of confidence from management. It adds:

NST announced the commencement of an on market Buy-back scheme of up to A$500m, representing ~1.6% of issued capital. The buy-back is separate from the dividend payout policy of 20-30% of cash earnings and will commence on the 23rd of April. The buy-back has minimal impact on our EPS estimates going forward, however the signalling of value in the underlying business is of more importance. As noted above, we see NST as hitting the bottom of production and earnings downgrades, with some margin compression to come from the impact of fuel prices.

Should you buy Northern Star shares?

According to the note, the broker has retained its buy rating and $35.00 price target on Northern Star’s shares.

Based on its current share price of $24.47, this implies potential upside of 43% for investors over the next 12 months.

In addition, the broker is expecting a 2.6% dividend yield over the period, boosting the total potential return beyond 45%.

The post Are Northern Star shares a cheap buy? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• March was the worst month for the gold price since June 2013. Now what?
• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday
• Why Greatland Resources, Newmont, Northern Star, and Qantas shares are rising today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In what has been a volatile start to 2026, ASX healthcare shares have been amongst the sharemarket losers. 

The S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen almost 17% year to date. 

However, there are opportunities to find value for investors. 

Let’s look at three ASX healthcare shares drawing positive outlooks from experts. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation. 

This process treats cancerous or diseased cells, an alternative approach to many cancer therapies, which also attack healthy tissue at the same time.

Telix shares have rebounded over the past couple of months, rising 55% since mid February. 

Telix shares rose in March largely because several value-driving catalysts hit at once, improving both fundamentals and investor sentiment.

However, they remain down 48% over the last year. 

In good news for investors, brokers are expecting Telix shares to recover even further. 

Recently, Bell Potter retained its buy rating and $19 price target on this radiopharmaceuticals company’s shares. 

From yesterday’s closing price of $13.64, this indicates a further upside of roughly 39%. 

Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma Group is another ASX healthcare stock that is down significantly from yearly highs. 

It has fallen 32% year to date. 

This includes a 6% decline yesterday, as investors may have reacted negatively to fresh tariff worries.

However, the company is confident the new tariffs will have “no material impact” on its FY27 earnings profile.

The stock price closed yesterday at $2.16, and after the recent fall, it may be another value play.

Two analysts’ forecasts via TradingView have an average one-year price target of $5.75 on the stock, indicating more than 160% upside. 

EBR Systems Inc (ASX: EBR)

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. 

The company’s Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

It is down roughly 30% year to date. However, it is also drawing positive ratings from brokers. 

Yesterday, the company released a preliminary version of its operating metrics. 

The report showed strong Q1 2026 growth in commercial cases.

This prompted Bell Potter to release updated guidance on this ASX healthcare stock along with a price target of $2, indicating a potential 194% rise. 

The post Where is the value amongst ASX healthcare shares? appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• Bell Potter says this ASX healthcare stock could rise nearly 200%
• Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today
• Top brokers name 3 ASX shares to buy today
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Aaron Bell has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Monadelphous Group Ltd (ASX: MND) share price is in focus after the company reported it has secured approximately $145 million in new contracts and contract extensions in the resources sector. Highlights include a major project at Rio Tinto’s (ASX: RIO) Paraburdoo iron ore mine and contract extensions at BHP Group Ltd (ASX: BHO) and Queensland Alumina Limited.

What did Monadelphous report?

• New contracts and extensions valued at around $145 million in total
• Secured a Rio Tinto construction project at Paraburdoo iron ore mine in WA
• Two-year extension to Olympic Dam maintenance contract with BHP in SA
• Two-year extension and expanded scope at Queensland Alumina Limited in QLD
• New construction contract with Harmony Gold at Hidden Valley Gold Mine, PNG

What else do investors need to know?

Monadelphous’ work for Rio Tinto at Paraburdoo involves installing a new dust collector and ventilation system for coarse ore stockpile tunnels, with completion expected in early 2027. The company’s relationship with BHP has also been extended, covering mechanical and electrical maintenance, planned shutdowns, and project services at Olympic Dam.

At Queensland Alumina in Gladstone, Monadelphous has secured both a contract extension and expanded responsibilities, now including demolition and power generation activities. The company’s expertise in the sector is reinforced by more than 30 years of service at this site.

What’s next for Monadelphous?

Looking ahead, Monadelphous plans to deliver on these newly awarded and extended contracts while continuing to grow its presence in resources, energy, and infrastructure markets. The company remains focused on leveraging its long-standing client relationships and diversified capabilities to pursue further opportunities, both domestically and internationally.

Monadelphous share price snapshot

Over the past 12 months, Monadelphous shares have risen 100%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Monadelphous wins $145m of new and renewed resources sector contracts appeared first on The Motley Fool Australia.

More reading

• Fortescue accelerates world’s first large-scale industrial green energy grid
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday
• Buy, hold, or sell? South32, Capstone Copper, and BHP shares

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Fortescue Ltd (ASX: FMG) share price is in the spotlight after the company announced it is fast-tracking the delivery of the world’s first large-scale, integrated green energy grid for heavy industry. Fortescue expects to eliminate diesel use ahead of its previous targets and is projecting significant cost savings from its decarbonisation program.

What did Fortescue report?

• Accelerating its green industrial energy grid, targeting completion by end of 2028
• 290MW of renewable capacity to be installed by early next year, powering “green processing” at Pilbara sites
• Full grid to include 1.2GW of solar, over 600MW wind, and 4–5GWh battery storage
• Targeting approximately 2GW total generation capacity upon program completion
• Forecasting US$100 million in fossil fuel cost savings by next year
• Anticipated C1 unit cost reduction of at least US$2–$4/wet metric tonne

What else do investors need to know?

Fortescue’s grid operates off-grid, using its own renewable generation rather than relying on national networks, supporting industrial operations around the clock. The project leverages proprietary AI-driven optimisation, in-house developed technology, and aims to demonstrate the commercial and operational advantages of full decarbonisation in mining.

The company plans to expand capacity by an extra 2GW, with advanced batteries, at a capital cost below US$2.5 billion if future investment decisions proceed. Fortescue will offer its systems as licences or services globally and has received early interest from other large shippers and countries.

What’s next for Fortescue?

With construction underway, Fortescue expects its Pilbara green grid to power all operations for 24-hour periods fossil fuel–free by late next year. Longer-term, the company is targeting full completion by the end of 2028, reducing cost volatility and improving energy certainty.

Fortescue intends to replicate this green grid technology globally, anticipating accelerated timelines and reduced costs with further deployments. The company is positioning to license or provide its end-to-end green energy system to major industrial energy users worldwide.

Fortescue share price snapshot

Over the past 12 months, Fortescue shares have risen 36%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Fortescue accelerates world’s first large-scale industrial green energy grid appeared first on The Motley Fool Australia.

More reading

• Monadelphous wins $145m of new and renewed resources sector contracts
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday
• Orora updates FY26 outlook as Saverglass earnings take a hit

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in the spotlight after the FDA accepted its New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent for glioma. TLX101-Px has received Orphan Drug and Fast Track status, with a key regulatory decision expected by September.

What did Telix Pharmaceuticals report?

• The US FDA accepted Telix’s NDA for TLX101-Px (Pixclara®), a PET agent for imaging brain cancer (glioma)
• The Prescription Drug User Fee Act (PDUFA) goal date is 11 September 2026
• TLX101-Px holds Orphan Drug and Fast Track designations in the US
• No FY 2026 revenue guidance has been assigned to TLX101-Px pending approval
• TLX101-Px aimed at addressing an unmet medical need in both adult and paediatric glioma cases

What else do investors need to know?

The FDA’s acceptance of the Telix NDA marks a key step toward potential commercialisation of TLX101-Px in the United States. This diagnostic agent aims to improve the differentiation between recurrent glioma and treatment-related changes, a persistent challenge in neuro-oncology.

TLX101-Px is expected to complement Telix’s broader LAT1-targeting therapeutic pipeline, notably the TLX101-Tx therapy under investigation in the IPAX-BrIGHT clinical trial. There are currently no marketing authorisations for TLX101-Px or TLX101-Tx in any region.

Telix has reaffirmed that FY 2026 guidance does not anticipate revenue for TLX101-Px, pending the FDA decision. The product could provide both clinical impact and financial upside if approved in the future.

What’s next for Telix Pharmaceuticals?

Investors can expect further updates as Telix works with the FDA ahead of the September 2026 goal date for TLX101-Px. The company is also advancing late-stage trials for related therapies, aiming to build a broader radiopharmaceutical portfolio for oncology and rare diseases.

Looking ahead, a successful approval could see Telix expand its presence in the US diagnostics market while pursuing commercial opportunities for both imaging and therapeutic candidates.

Telix Pharmaceuticals share price snapshot

Over the past year, Telix Pharmaceuticals shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: FDA accepts Pixclara NDA appeared first on The Motley Fool Australia.

More reading

• Where is the value amongst ASX healthcare shares?
• Monadelphous wins $145m of new and renewed resources sector contracts
• Fortescue accelerates world’s first large-scale industrial green energy grid
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

I think putting money to work in the share market is always a good idea.

Regardless of the amount, what matters most is choosing businesses with strong long-term potential and building the habit of investing consistently.

The good news is that the Australian share market is home to many businesses that tick these boxes in 2026.

So, if I had $2,000 to invest today, these are three ASX shares I would consider buying in April.

Breville Group Ltd (ASX: BRG)

Breville is a business I think is often underestimated. It operates in premium kitchen appliances, but what stands out to me is how it has built a global brand. Its products are sold across multiple regions, and it continues to expand into new markets.

What I like is the combination of product innovation and international growth. The company has shown it can introduce new products that resonate with consumers while also scaling its distribution globally.

That gives it multiple avenues for growth over time.

Xero Ltd (ASX: XRO)

Xero offers exposure to software and digital transformation. The company provides accounting software to small and medium-sized businesses, and that shift toward cloud-based solutions is still ongoing.

The share price has been under pressure, partly due to concerns around competition and artificial intelligence (AI). But I think the long-term opportunity remains intact.

Xero has built a strong ecosystem and continues to grow its subscriber base, which supports recurring revenue. For me, it is a business that could continue compounding if it executes well.

Pro Medicus Ltd (ASX: PME)

Pro Medicus is one of the more impressive growth stories on the ASX. It operates in the medical imaging software market, providing solutions to hospitals and healthcare providers worldwide.

What stands out is the quality of the business. High margins, strong cash flow, and a growing list of major contracts all point to a company that is scaling effectively.

Healthcare demand is also supported by long-term trends, which give it a favourable backdrop.

Its valuation can look demanding at times, but I think that reflects the strength of the business and its positive long-term growth outlook.

Foolish Takeaway

A $2,000 investment can be the start of something meaningful.

Breville offers global consumer growth, Xero provides exposure to software and recurring revenue, and Pro Medicus brings high-quality healthcare growth.

Importantly, all three have the potential to grow over time, and that is what matters most to me when putting money to work.

The post $2,000 to invest? 3 ASX shares to consider today appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares just upgraded to strong buy ratings
• 3 reasons to buy Xero shares now
• 2 ASX 200 shares I rate as top buys for growth
• I’m following Warren Buffett to snap up these cheap ASX stocks
• 3 ASX shares tipped to grow 100% or more in the next 12 months

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.